

**EARNINGS
UPDATE
Q1 FY 2022**

2021

22



DISCLAIMER

- No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be “forward looking statements” based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.
- Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.
- Numbers mentioned in this Presentation in respect of information provided on hospital operating parameters and other operating metrics have been compiled by the management and are being provided only by way of additional information. These are not to be construed as being provided under any legal or regulatory requirements. The accuracy of these numbers have neither been vetted nor approved by the Audit Committee and the Board of Directors of Apollo Hospitals Enterprise Limited (AHEL), nor have they been vetted or reviewed by the Auditors, and therefore may differ from the actual.
- Important risk factors and uncertainties could make a material difference to the Company’s operations. These risks include but are not limited to, the risk factors described in AHEL’s prospectus, annual reports and other periodic filings made by the company. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statement, on the basis of any subsequent development, information or events, or otherwise.
- This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes. This presentation may not be copied or disseminated in any manner.
- The Company on a quarterly basis adopts and publishes Standalone & Consolidated financial results as per the stock exchange listing agreement requirements.
- Previous year figures have been reworked/regrouped /rearranged and reclassified wherever necessary to conform to the requirement of revised Schedule VI format.

Key Highlights

01

HIGHLIGHTS

02

**STANDALONE FINANCIAL
PERFORMANCE**

03

**CONSOLIDATED FINANCIAL
PERFORMANCE**

04

**OPERATIONAL PARAMETERS -
HOSPITALS & PHARMACIES**

05

APOLLO 24/7

06

**APOLLO HEALTH & LIFESTYLE
LTD**



01

HIGHLIGHTS



HIGHLIGHTS

Financial Performance Q1 FY22

- Q1 FY22 Consolidated Revenues of ₹ 37,602 mio (growth of 73% yoy).
- Q1 FY22 Consolidated EBITDA (Post Ind AS 116) of ₹ 5,199 mio.
- New Hospitals (excl Proton) reported an EBITDA of ₹ 1,024 mio in Q1 FY22 as compared to an EBITDA loss of ₹ (251) mio in Q1 FY21.
- Proton reported EBITDA (Post Ind AS 116) of ₹ 106 mio in Q1 FY22 as compared to EBITDA loss of ₹ (34) mio in Q1 FY21.
- AHLL reported EBITDA (Post Ind AS 116) of ₹ 479 mio in Q1 FY22 as compared to EBITDA loss of ₹ (27) mio in Q1FY21.
- Consolidated PAT of ₹ 4,893 mio in Q1 FY22, includes Exceptional gain of ₹ 2,941mio (Fair value remeasurement of existing interest in AMHL). PAT (excluding the exceptional gain) ₹ 1,952 mio.
- Ind-AS 116 on operating lease impacted reported PBT in Q1FY22 to the extent of ₹ 118 mio

Key Operational Highlights Q1 FY22

- Q1FY22 occupancy across the group was at 5,108 beds (67% occupancy) as compared to 2,742 beds (38% occupancy) in Q1FY21. The Q1FY22 occupancy in mature hospitals was at 3,500 beds (64% occupancy). New hospitals had an occupancy of 1,607 beds (73%) occupancy) in Q1FY22.
- Inpatient Volumes across the group increased by 53% from 63,105 to 96,704.
- ARPOB (excluding vaccination) was at ₹ 41,102 Vs ₹ 38,065 registering a growth of 8% in Q1FY22 as compared to the previous year.



HIGHLIGHTS

Capacity

- 71 hospitals with total bed capacity of 10,209 beds as on June 30, 2021.
 - 44 owned hospitals including JVs/ Subsidiaries and Associates with 8,816 beds.
 - 11 Day care/ short surgical stay centres with 270 beds and 11 Cradles with 272 beds.
 - 5 Managed hospitals with 851 beds.
- Of the 8,816 owned hospital beds capacity, 7,647 beds were operational and had an occupancy of 67% in Q1 FY22.
- The total number of pharmacies as on June 30, 2021 was 4,163. Gross additions of 62 stores and closed 17 stores; Net addition of 45 stores in Q1 FY22

Medical Initiatives Accomplishments


- Apollo Hospitals, Hyderabad successfully performed a complex combined liver and kidney transplant by using one organ from a non-matching blood group
- Apollo Hospitals, Chennai successfully performed a fusion less scoliosis surgery on a female patient from the United States of America who was affected by idiopathic Scoliosis, an abnormal curvature of the spine
- A Cyber Knife Radiosurgery procedure was successfully performed by Apollo Cancer Centre, Chennai on a 34-year-old athlete from New Zealand, relieving him from symptoms of a special form of epilepsy called Medial temporal lobe Epilepsy (MTLE) while preserving his memory

Other Key Developments

- Apollo Proton Cancer Centre launched a dedicated Robot-Assisted Cancer Surgery Unit equipped with the advanced fourth-generation 'Da Vinci Surgical System'.
- Apollo Specialty Hospitals, Jayanagar, Bangalore bagged the Centre of Excellence award by The Deccan Herald Healing Hands Initiative in recognition for the work during COVID-19.



COVID TESTING AND TREATMENT – Q1FY22



- 'Project Stay I' saw success with over 24,000 room nights.
- Our effort in the Home care segment enabled us to move into 29,000 homes, (of which COVID care was at 20,000 homes) and provide medically supervised home isolation services
- Digital healthcare app Apollo 24/7 – agile and digitally connected to the consumer, over 2 lakh digital consults during the Quarter.



02

STANDALONE FINANCIAL PERFORMANCE



STANDALONE FINANCIAL PERFORMANCE

TOTAL

(₹ mio)

	Q1 FY 21	Q1 FY 22	yoy (%)
Revenue	19,615	29,947	52.7%
Operative Expenses	11,703	18,424	57.4%
Employee Expenses	3,768	3,180	-15.6%
Administrative & Other Expenses	3,730	4,437	18.9%
Total Expenses	19,201	26,041	35.6%
EBITDA (Post Ind AS 116)	415	3,906	842.3%
<i>margin (%)</i>	2.1%	13.0%	1093 bps
Depreciation	1,264	960	-24.1%
EBIT	-850	2,946	-446.6%
<i>margin (%)</i>	-4.3%	9.8%	1417 bps
Financial Expenses	1,026	638	-37.9%
Other Income	17	87	418.0%
Exceptional item*		-67	
Profit Before Tax	-1,859	2,328	-225.2%
Profit After Tax	-1,491	1,500	-200.6%
<i>margin (%)</i>	-7.6%	5.0%	1261 bps

Total Debt		25,507	
Cash & Cash equivalents (includes investment in liquid funds)		8,860	
Net Debt		16,647	

Key Highlights

- Q1 FY22 Revenues at ₹ 29,947 mio
- Q1 FY22 EBITDA at ₹ 3,906 mio
- Q1 FY22 EBIT of ₹ 2,946 mio
- Q1 FY22 PAT of ₹ 1,500 mio

*Provision towards loan to Apollo Lavasa Health Corp Ltd



STANDALONE FINANCIAL PERFORMANCE

MATURE & NEW BREAKUP – Q1 FY22

(₹ mio)

		Healthcare Services (Mature)	New Hospitals	Proton	Healthcare Services (Total)	Pharmacy Distribution*	Standalone
Q1 FY 22	Hospitals	21	10	1	32		
	Operating beds	3,310	1,583	53	4,946		
	Occupancy	63%	74%	63%	66%		
	Revenue	9,830	4,558	439	14,827	15,120	29,947
	EBITDA (Post Ind AS 116)**	2,272	745	106	3,123	1,153	4,276
	margin (%)	23.1%	16.3%	24.2%	21.1%	7.6%	14.3%
	24/7 Operating Costs					-370	-370
	EBITDA (Post Ind AS 116)	2,272	745	106	3,123	783	3,906
	margin (%)	23.1%	16.3%	24.2%	21.1%	5.2%	13.0%
	EBIT	1,775	490	9	2,274	672	2,946
margin (%)	18.1%	10.7%	2.1%	15.3%	4.4%	9.8%	
Q1 FY 21	Hospitals	21	10	1	32		
	Operating beds	3,119	1,482	53	4,654		
	Occupancy	37%	35%	25%	36%		
	Revenue	4,840	1,792	192	6,824	12,791	19,615
	EBITDA (Post Ind AS 116)	-510	-261	-34	-805	1,220	414
	margin (%)	-10.5%	-14.6%		-11.8%	9.5%	2.1%
	EBIT	-1,021	-521	-128	-1,670	820	-850
	margin (%)	-21.1%	-29.1%		-24.5%	6.4%	-4.3%

Key Highlights

- HCS revenue at ₹ 14,827 mio in Q1FY22 growth of 117%
 - Mature HCS revenue at ₹ 9,830 mio
 - New HCS revenue at ₹ 4,558 mio.
- HCS EBITDA at ₹ 3,123 mio in Q1FY22
 - Mature HCS EBITDA at ₹ 2,272 mio (23.1% margin)
 - New HCS EBITDA at ₹ 745 mio (16.3% margin)
- Pharmacy Distribution revenue at ₹ 15,120 mio and EBITDA was at ₹ 1,153 mio (7.6% margin)

*Pharmacy Distribution from 1st Sep 2020 ** EBITDA Post Ind AS 116 - excluding 24/7 operating costs



STANDALONE FINANCIAL PERFORMANCE

SEGMENT REPORTING

(₹ mio)

	Q1 FY 21	Q1 FY 22	yoy (%)
Revenues from each segment			
Healthcare Services*	6,824	14,827	117.3%
Stand-alone Pharmacy	12,791		
Pharmacy Distribution**	0	15,120	
Total	19,616	29,947	52.7%
Less: Intersegmental Revenue	1		
Net Revenues	19,615	29,947	52.7%
Profit before Tax & Interest (EBIT)			
Healthcare Services*	-1,670	2,274	-236.2%
Stand-alone Pharmacy	820		
Pharmacy Distribution**		672	
Total EBIT	-850	2,946	-446.6%
Profit before Tax & Interest (EBIT) margins			
Healthcare Services*	-24.5%	15.3%	3980 bps
Stand-alone Pharmacy	6.4%		
Pharmacy Distribution**		4.4%	
Total EBIT margin	-4.3%	9.8%	1417 bps
		Capital employed ⁽¹⁾	ROCE
Healthcare services		54,495	16.7%
Pharmacy Distribution		8,525	31.5%
Capital employed		63,020	18.7%

*Healthcare Services consists of Hospitals, Hospital Based Pharmacies and Consulting

**Pharmacy distribution represents the exclusive pharmacy distribution backend business for Apollo Pharmacies Ltd (SAP business) from 1st Sep 2020

⁽¹⁾ Capital employed for the calculation of ROCE does not include Capital Work in progress of new hospitals of ₹ 672 mio and ₹ 21,444 mio for Investment in Subs, Associates and Mutual funds as at June 21. The Capital employed as per segment reporting does not include Investments in Subs & JVs as the results of these companies don't form part of Standalone financials.



03

**CONSOLIDATED FINANCIAL
PERFORMANCE**



CONSOLIDATED FINANCIAL PERFORMANCE

TOTAL

(₹ mio)

	Q1 FY 21	Q1 FY 22	yoy (%)
Total Revenues	21,715	37,602	73.2%
EBITDA (Post Ind AS 116)	355	5,199	1365.3%
<i>margin (%)</i>	<i>1.6%</i>	<i>13.8%</i>	<i>1219 bps</i>
EBIT	-1,247	3,793	-404.1%
<i>margin (%)</i>	<i>-5.7%</i>	<i>10.1%</i>	<i>1583 bps</i>
Profit After Tax	-2,082	4,893	-335.0%
Exceptional Item *		2,941	
Profit After Tax(excluding Exceptional Item)		1,952	
Total Debt		31,545	
Cash & Cash equivalents (includes investment in liquid funds)		13,607	
Net Debt		17,938	

Key Highlights

- Q1FY22 Consolidated Revenues at ₹ 37,602 mio
- Q1FY22 Consolidated EBITDA of ₹ 5,199 mio
- Q1FY22 Consolidated PAT of ₹ 4,893 mio
Excluding the exceptional gain the PAT was at ₹ 1,952 mio

*Fair Value Gain on remeasurment of existing interest in JV(AMHL earlier know as AGHL) under Ind AS 103 Business Combination.



CONSOLIDATED FINANCIAL PERFORMANCE

MATURE & NEW BREAKUP – Q1 FY22

(₹ mio)

		Healthcare Serv Group (Mature)	Healthcare Serv Group (New & Others)	Proton	Healthcare Serv Group (Total)	Pharmacy Distribution*	AHLL	Consol
Q1 FY 22	Hospitals	30	13	1	44			
	Operating beds	5,437	2,157	53	7,647			
	Occupancy	64%	73%	63%	67%			
	Revenue	12,682	6,271	439	19,392	15,120	3,090	37,602
	EBITDA (Post Ind AS 116)**	2,806	1,024	106	3,936	1,153	479	5,569
	margin (%)	22.1%	16.3%	24.2%	20.3%	7.6%	15.5%	14.8%
	24/7 Operating Costs					-370		-370
	EBITDA (Post Ind AS 116)	2,806	1,024	106	3,936	783	479	5,199
	margin (%)	22.1%	16.3%	24.2%	20.3%	5.2%	15.5%	13.8%
	EBIT	2,158	697	9	2,864	672	257	3,793
margin (%)	17.0%	11.1%	2.1%	14.8%	4.4%	8.3%	10.1%	
Q1 FY 21	Hospitals	30	13	1	44			
	Operating beds	5,247	1,967	53	7,267			
	Occupancy	37%	40%	25%	38%			
	Revenue	5,430	2,277	192	7,899	12,791	1,024	21,715
	EBITDA (Post Ind AS 116)	-552	-251	-34	-838	1,220	-27	355
	margin (%)	-10.2%	-11.0%		-10.6%	9.5%	-2.7%	1.6%
	EBIT	-1,145	-548	-128	-1,821	820	-245	-1,247
margin (%)	-21.1%	-24.1%		-23.1%	6.4%		-5.7%	

*Pharmacy Distribution from 1st Sep 2020

**EBITDA Post Ind AS 116 - excluding 24/7 operating costs

Key Highlights

- HCS revenue at ₹ 19,392 mio in Q1FY22, growth of 145%
 - Mature HCS revenue at ₹12,682 mio
 - New HCS revenue at ₹ 6,271 mio
- HCS EBITDA at ₹ 3,936 mio in Q1FY22
 - Mature HCS EBITDA at ₹2,806 mio (22.1% margin)
 - New HCS EBITDA at ₹1,024 mio (16.3% margin)
- AHLL – Cradle & Clinics reported Revenue of ₹ 3,090 mio, EBITDA of ₹ 479 mio (15.5% margin)



04

OPERATIONAL PARAMETERS - HOSPITALS & PHARMACIES



OPERATIONAL PARAMETERS - HOSPITALS

(₹ mio)

Particulars	Total ⁽⁶⁾			Tamilnadu Region (Chennai & others) ⁽¹⁾			AP, Telangana Region (Hyderabad & others) ⁽²⁾			Karnataka Region (Bangalore & others) ⁽³⁾			Others ⁽⁴⁾			Significant Subs/JVs/associates ⁽⁵⁾		
	Q1 FY 21	Q1 FY 22	yoy (%)	Q1 FY 21	Q1 FY 22	yoy (%)	Q1 FY 21	Q1 FY 22	yoy (%)	Q1 FY 21	Q1 FY 22	yoy (%)	Q1 FY 21	Q1 FY 22	yoy (%)	Q1 FY 21	Q1 FY 22	yoy (%)
No. of Operating beds	7,267	7,647		1,926	2,133		1,344	1,344		810	845		962	1,012		2,225	2,313	
Inpatient volume	63,105	96,704	53.2%	13,582	24,358	79.3%	8,428	14,799	75.6%	8,435	12,775	51.5%	13,307	16,431	23.5%	19,353	28,341	46.4%
Outpatient volume ⁽⁷⁾	153,479	820,738	434.8%	38,777	313,800	709.2%	23,356	89,876	284.8%	22,044	77,178	250.1%	23,699	71,331	201.0%	45,603	268,553	488.9%
Inpatient ALOS (days)	3.95	4.81		4.07	4.91		4.20	5.17		3.16	4.54		3.78	4.31		4.23	4.93	
Bed Occupancy Rate (%)	38%	67%		32%	62%		29%	63%		36%	75%		58%	77%		40%	66%	
Inpatient revenue (₹ mio)	NA	NA		2,127	5,116	140.6%	1,301	3,587	175.8%	907	2,214	144.1%	1,200	2,235	86.2%	2,343	5,130	119.0%
Outpatient revenue (₹ mio)	NA	NA		443	1,195	170.1%	250	599	139.1%	186	555	198.0%	182	346	89.9%	444	1,320	197.1%
ARPOB (₹ /day) ^{(8)excluding Vaccination}	38,065	41,102	8.0%	46,473	50,466	8.6%	43,862	49,853	13.7%	41,035	41,626	1.4%	27,451	32,592	18.7%	34,060	43,261	27.0%
Total Net Revenue (₹ mio) ⁽⁶⁾	NA	NA		2,569	6,311	145.6%	1,551	4,186	169.9%	1,093	2,769	153.3%	1,383	2,581	86.7%	2,787	6,450	131.4%

Notes:

(1) Tamilnadu region includes Chennai hospitals, Madurai, Karur, Karaikudi, Trichy & Nellore.

(2) AP, Telangana Region includes Hyderabad, Karimnagar, Vizag old, Vizag new & Kakinada.

(3) Karnataka region includes Bangalore, Mysore, Jayanagar & Malleswaram.

(4) Others include Bhubaneswar, Bilaspur, Nashik & Navi Mumbai.

(5) Significant Hospital JVs/Subs/Associates are – Ahmedabad, Kolkata, Delhi, Indore, Assam & Lucknow (full revenues shown in table above).

(6) Revenues under the head “Total” have not been provided as Consolidated actual results will differ from total due to proportionate consolidation.

(7) Outpatient volume represents New Registrations only.

(8) Revenues under Ind AS have been grossed up for Fixed fee Doctors & considered separately as operating cost. This was earlier being netted off from Revenues under Indian GAAP. ARPOB excludes Vaccination Revenue



PHARMACY DISTRIBUTION

(₹ mio)

	Q1 FY 21	Q1 FY 22*	yoy (%)
Revenue	12,791	15,120	18.2%
EBITDA (Post Ind AS 116)	1,220	1,153	-5.5%
<i>margin (%)</i>	9.5%	7.6%	-191 bps

*Pharmacy Distribution from 1st Sep 2020

- The Combined Pharmacy platform business reported revenue of ₹ 18,293 mio in Q1FY22 as compared to a Revenue of ₹ 12,791 mio in Q1FY21, **43% growth**.
 - The like-to-like EBITDA (Post Ind As 116) in Q1FY22 was at ₹ 1,455 mio as compared to ₹ 1,220 mio in Q1FY21, growth of 19%.
- **No of Pharmacies : 4,163**
Added 62 stores and Closed 17 Stores in Q1FY22.
Net addition of 45 Stores
- Private Label sales at **13.24%** of Revenues in Q1FY22



05

APOLLO 24/7

APOLLO 24X7 – INDIA'S LARGEST OMNI-CHANNEL HEALTHCARE PLATFORM LEVERAGING PHYSICAL NETWORK




Digital services

Physical network & capabilities

Distinctive digital ecosystem ...

Part of Apollo 24/7




Enablers provided by Apollo Group Companies (unique & other players cannot provide)

... coupled with formidable physical network & capabilities


Distinctive digital ecosystem...

Cumulative upto 30th June 2021



- Unique ecosystem extremely difficult to replicate
- Integrated healthcare platform with few parallels globally
- Best positioned to become the largest digital health platform


... coupled with adequate network and capabilities



- Cost efficiencies through sharing of managerial and clinical resources
- Economies of scale & competitive prices through centralized purchasing
- Access to qualified & trained medical resources and larger patient base



Awaiting Shareholders approval on 14th August for Reorganization through Slump Sale



Slump Sale of the identified business undertaking into AHL including the following

- Back-end pharmacy supply (excludes Hospital Based Pharmacies)
- Apollo 24/7 Digital healthcare Platform
- Investment in pharmacy retail business (i.e. Apollo Medicals Private Limited)
- “Apollo 24/7” brand, the “Apollo Pharmacy” brand and private label brands

- Apollo 24/7 represents Apollo Group’s transformational journey to creating “India’s Largest Omnichannel Digital Healthcare Platform” that:
 - combines the strengths of Apollo Group’s offline healthcare leadership with Apollo Group’s new-age digital offerings to address all healthcare consumer needs;
 - involves an asset light approach (through digital offerings) to fuel growth – 100 million targeted registered users on Apollo 24/7 platform in 5 years.
 - presents huge funnelling potential for healthcare consumers into the Apollo Group ecosystem.
- Structure to set the platform for a new pool of investor capital and to enable rapid scale-up. At the time of capital raise, AHL valuation to reflect current and future growth potential.
- Post external capital raise at AHL,
 - AHEL expected to retain dominant majority shareholding in AHL; and
 - Slump sale consideration of INR Rs 1,210 crs will be received by AHEL.



06

APOLLO HEALTH & LIFESTYLE LTD



(₹ mio)

	Clinics	Diagnostics	Sugar	Dental	Dialysis	Cradles (IP)	IVF	Spectra (IP)
Network	197	847	21	63	75	8	12	11
Footfalls/Day*	6796	13995	303	77	1096	38	14	53
Gross ARPP (Rs.)*	1567	610	2324	6690	1488	106474	35518	106912



		Diagnostics	Primary Care	Specialty Care	Corporate	Intra Group	AHLL (Consol)
Gross Revenue	Q1 FY22	1066	1065	1119	0	-160	3,090
	Q1 FY21	218	241	607	0	-41	1,024
Net Revenue	Q1 FY22	1040	825	789	0	-159	2,495
	Q1 FY21	200	189	409	0	-40	758
EBITDA [with Ind AS 116]	Q1 FY22	286	142	130	-78	0	479
	Q1 FY21	-13	-14	49	-50	0	-27
EBITDA (with out Ind AS 116)	Q1 FY22	268	99	11	-78	0	300
	Q1 FY21	-26	-58	-57	-50	0	-191
EBIT	Q1 FY22	262	84	-7	-82	0	257
	Q1 FY21	-51	-110	-84	-1	0	-245
PAT	Q1 FY22	251	58	-104	-73	0	131
	Q1 FY21	-39	-84	-160	-65	0	-348

Key Highlights

AHLL reported EBITDA of ₹ 479 mio as compared to a loss of ₹ (27) mio in Q1 FY21

* Footfalls and ARPP for diagnostics represent outpatient / external business and for Cradle and Spectra it represents Inpatient volumes.

Primary care includes Clinics, Sugar, Dental and Dialysis segments. Specialty care includes Cradles and Spectra



APPENDIX 1 : IND AS - 116

IMPACT ON P&L AND BALANCE SHEET – Q1FY22

(₹ mio)

AHEL Standalone (post IND AS 116)



Balance sheet

Right of use Asset as of 30 th June, 2021	↑	6,002
Lease liabilities as of 30 th June, 2021	↑	7,863
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax)	↓	2,109



Profit & Loss

Revenue	-
Other expenses (Lease rent)	↓ 211
EBITDA	↑ 211
Amortisation	↑ 115
EBIT	↑ 96
Finance charge	↑ 163
PBT	↓ 67

AHEL Consolidated (post IND AS 116)



Balance sheet

Right of use Asset as of 30 th June, 2021	↑	9,981
Lease liabilities as of 30 th June, 2021	↑	13,288
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax)	↓	3,052



Profit & Loss

Revenue	-
Other expenses (Lease rent)	↓ 423
EBITDA	↑ 423
Amortisation	↑ 255
EBIT	↑ 168
Finance charge	↑ 285
PBT	↓ 118

Note: Accounting increase in Assets & Liabilities in the Balance sheet (due to Right of Use Asset) optically suppresses the ROCE and increases the leverage ratios. No real impact in actual business ROCE.



APPENDIX 2 : BASIS OF CONSOLIDATION

AHEL Standalone	Location	Description	AHEL Ownership
Chennai Main	Chennai	Hospital	100.00%
ACI - Chennai	Chennai	Hospital	
Tondiarpet - Chennai	Chennai	Hospital	
FirstMed - Chennai	Chennai	Hospital	
Apollo Children's Hospital	Chennai	Hospital	
Apollo Specialty, Vanagaram	Chennai	Hospital	
Women & Child, OMR	Chennai	Hospital	
ASH Perungudi	Chennai	Hospital	
Women & Child, Shafee Mohammed Road	Chennai	Hospital	
Apollo Proton & Cancer care	Chennai	Hospital	
Madurai	Madurai	Hospital	
Karur	Karur	Hospital	
Karaikudi	Karaikudi	Hospital	
Trichy	Trichy	Hospital	
Nellore	Nellore	Hospital	
Hyderabad	Hyderabad	Hospital	
Bilaspur	Bilaspur	Hospital	
Mysore	Mysore	Hospital	
Vizag (old & new)	Vizag	Hospital	
Karim Nagar	Karim Nagar	Hospital	
Bhubaneswar	Bhubaneswar	Hospital	
Jayanagar	Bangalore	Hospital	
Nashik	Nashik	Hospital	
Vizag New	Vizag	Hospital	
Malleswaram	Bangalore	Hospital	
Navi Mumbai	Mumbai	Hospital	

Subsidiaries	Location	Description	AHEL Ownership
Samudra Healthcare Enterprises Ltd.	Kakinada	Hospital	100.00%
Apollo Hospitals (UK) Ltd	UK	Hospital	100.00%
AB Medical Centres Limited	Chennai	Infrastructure	100.00%
Total Health			100.00%
Apollo Hospitals Singapore.PTE Limited			100.00%
Future Parking Pvt Ltd	Chennai	Infrastructure	100.00%
Apollo Multispeciality Hospitals Ltd.	Kolkata	Hospital	100.00%
Imperial Hospital and Research Centre Ltd.	Bangalore	Hospital	90.00%
Apollo Home Health care Ltd	Hyderabad	Paramedical Services	89.42%
Pinakini Hospitals Ltd.	Nellore	Hospital	80.87%
Sapien Biosciences Pvt Ltd	Hyderabad	Biobanking tissues	70.00%
Apollo Health and Lifestyle Ltd.	Hyderabad	Apollo Clinics	68.20%
Assam Hospitals Ltd	Assam	Hospital	66.48%
Apollo Rajshree Hospital	Indore	Hospital	54.63%
Apollo Lavasa Health Corporation Ltd	Maharashtra		51.00%
Apollo Medics	Lucknow	Hospital	51.00%
Apollo Hospitals International Ltd.	Ahmedabad	Hospital	50.00%
Apollo Healthcare Technology Solutions Ltd	Chennai	Hospital	40.00%
Associates	Location	Description	
Indraprastha Medical Corporation Ltd.	Delhi, Noida	Hospital	22.03%
Family Health Plan Ltd.		TPA, Health Insurance	49.00%
ApoKos Rehab Pvt Ltd	Hyderabad	Rehab Centre	50.00%
Stemcyte India Therapeutics Pvt Ltd	Ahmedabad	Stemcell Banking	24.50%
Apollo Gleneagles PET-CT Pvt Ltd	Hyderabad	Hospital	50.00%
Apollo Medicals Private Limited	Chennai	Pharmaceutical	25.50%

THANK

YOU